Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
111
datasets available to search
ShareScore release 0.9.0
Dataset results
111 results for “drug resistant epilepsy”
Voronistat in Pediatric Patients With Drug Resistant Epilepsy
ClinicalTrials.gov study NCT03894826. IPD Sharing: NO. Countries: 1. Publications: 2.
A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy
ClinicalTrials.gov study NCT06388707. IPD Sharing: NO. Countries: 1. Publications: 3.
Efficacy, Safety and Pharmacokinetics of ES-481 in Adult Patients With Drug Resistant Epilepsy
ClinicalTrials.gov study NCT04714996. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Impact of Thermocoagulation During Invasive EEG Monitoring in Children With Focal Drug-resistant Epilepsies
ClinicalTrials.gov study NCT02886650. IPD Sharing: Not stated. Countries: 1. Publications: 0.
TDCs to Treat Drug-resistant Epilepsy
ClinicalTrials.gov study NCT05825274. IPD Sharing: YES. Countries: 1. Publications: 3.
A Pilot Study to Evaluate the Efficacy and Safety of NaviFUS™ System Neuromodulating Treatment for Patients With Drug Resistant Epilepsy
ClinicalTrials.gov study NCT06492720. IPD Sharing: NO. Countries: 1. Publications: 3.
Usefulness of Sodium MRI in the Presurgical Assessment of Drug-resistant Partial Epilepsy
ClinicalTrials.gov study NCT02304029. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Transcranial Direct Current Electrical Stimulation (tDCS) in Drug-resistant Epilepsy
ClinicalTrials.gov study NCT04782869. IPD Sharing: NO. Countries: 1. Publications: 0.
STIMEP : Assessment of Subthalamic Nucleus Stimulation in Drug Resistant Epilepsy
ClinicalTrials.gov study NCT00228371. IPD Sharing: Not stated. Countries: 1. Publications: 9.
Drug Resistant Epilepsy: Clinical and Genetic Study
ClinicalTrials.gov study NCT04166305. IPD Sharing: NO. Countries: 1. Publications: 13.
Ketogenic Diet vs.Antiepileptic Drug Treatment in Drug Resistant Epilepsy
ClinicalTrials.gov study NCT00552526. IPD Sharing: Not stated. Countries: 1. Publications: 6.
The Efficacy and Safety of Minocycline in the Treatment of Drug-resistant Epilepsy in NORSE Patients
ClinicalTrials.gov study NCT05958069. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Data from: Generalized polyspike train: an EEG biomarker of drug-resistant idiopathic generalized epilepsy
Objective: To identify clinical and EEG biomarkers of drug resistance in adults with idiopathic generalized epilepsy. Methods: We conducted a case-control study consisting of a discovery cohort and a replication cohort independently assessed at two different centres. In each centre patients with idiopathic generalized epilepsy phenotype and generalized spike-wave discharges on EEG were classified as drug-resistant or drug-responsive. EEG changes were classified into pre-defined patterns and compared between the two groups in the discovery cohort. Factors associated with drug resistance in multivariable analysis were tested in the replication cohort. Results: The discovery cohort included 85 patients (29% drug-resistant and 71% drug-responsive). Their median age at assessment was 32 years and 50.6% were female. Multivariable analysis showed that having higher number of seizure types (3 vs. 1: odds ratio [OR]= 31.1, 95% confidence interval [CI] 4.5-214, p<0.001; 3 vs. 2: OR=14.6, 95% CI: 2.3-93.1, p=0.004) and generalized polyspike train (burst of generalized rhythmic spikes lasting less than 1 second) during sleep were associated with drug resistance (OR=10.8, 95% CI: 2.4-49.4, p=0.002). When these factors were tested in the replication cohort of 80 patients (27.5% drug-resistant and 72.5% drug-responsive; 71.3% female; median age 27.5 years), the proportion of patients with generalized polyspike train during sleep was also higher in the drug-resistant group (OR=4.0, 95% CI: 1.35-11.8, p=0.012). Conclusion: Generalized polyspike train during sleep may be an EEG biomarker for drug resistance in adults with idiopathic generalized epilepsy.
The cost effectiveness of surgery for drug resistant temporal lobe epilepsy in the US
<p><strong>Objective:</strong> Surgery is an effective but costly treatment for many patients with drug resistant temporal lobe epilepsy (DR-TLE). We aim to evaluate whether, in the United States, 1) surgery is cost-effective compared to medical management for patients deemed surgical candidates, 2) surgical evaluation is cost-effective for DR-TLE patients in general.</p> <p><strong>Methods:</strong> We use a semi-Markov model to assess the cost-effectiveness of surgery and surgical evaluation over a lifetime horizon. We use 2<sup>nd</sup> order Monte Carlo simulations to conduct probabilistic sensitivity analyses to estimate variation in model output. We adopt both healthcare and societal perspectives, including direct healthcare costs (e.g. surgery, AEDs) and indirect costs (e.g. lost earnings by patients and care providers.) We compare incremental cost-effectiveness ratio (ICER) to societal willingness-to-pay (~$100,000 per Quality Adjusted Life Year) to determine whether surgery is cost-effective.</p> <p><strong>Results:</strong> Epilepsy surgery is cost effective compared to medical management in surgically eligible patients by virtue of being cost saving ($328K vs. 423K) and more effective (16.6 QALY vs. 13.6 QALY) than medical management in the long run. Surgical evaluation is cost-effective in DR-TLE patients even if the probability of being deemed a surgical candidate is only 5%. From a societal perspective, surgery becomes cost effective within 3 years and 89% of simulations favor surgery over the lifetime horizon.</p> <p><strong>Conclusion:</strong> For surgically eligible DR-TLE patients, surgery is cost-effective. For DR-TLE patients in general, referral for surgical evaluation (and possible subsequent surgery) is cost-effective. DR-TLE patients should be referred for surgical evaluation without hesitation on cost-effectiveness grounds.</p>
The incidence and prevalence of drug resistant epilepsy: a systematic review and meta-analysis
<p><strong>Objective:</strong> In order to evaluate the incidence and prevalence of drug-resistant epilepsy (DRE) as well as its predictors and correlates, we conducted a systematic review and meta-analysis of observational studies.</p> <p><strong>Methods: </strong>Our protocol was registered with PROSPERO and the PRISMA and MOOSE reporting standards were followed. We searched MEDLINE, Embase, and Web of Science. We used a double arcsine transformation and random-effects models to carry out our meta-analyses. We performed random-effects meta-regressions using study-level data.</p> <p><strong>Results:</strong> Our search strategy identified 10,794 abstracts. Of these, 103 articles met our eligibility criteria. There was high inter-study heterogeneity and risk of bias. The cumulative incidence of DRE was 25.0 % (95% CI: 16.8, 34.3) in child studies but 14.6% (95% CI: 8.8, 21.6) in adult/mixed ages studies. The prevalence of DRE was 13.7% (95% CI: 9.2, 19.0) in population/community-based populations but 36.3% (95% CI: 30.4, 42.4) in clinic-based cohorts. Meta-regression confirmed that the prevalence of DRE was higher in clinic-based populations and in focal epilepsy. Multiple predictors and correlates of DRE were identified. The most reported of these were having a neurological deficit, an abnormal EEG, and symptomatic epilepsy. The most reported genetic predictors of DRE were polymorphisms of the ABCB1 gene.</p> <p><strong>Conclusions:</strong> Our observations provide a basis for estimating the incidence and prevalence of DRE, which vary between populations. We identified numerous putative DRE predictors and correlates. These findings are important to plan epilepsy services, including epilepsy surgery, a crucial treatment option for people with disabling seizures and DRE.</p>
The Effect of Probiotic Supplementation in Drug-resistant Epilepsy Patients
ClinicalTrials.gov study NCT03403907. IPD Sharing: NO. Countries: 0. Publications: 3.
A Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal Epilepsy
ClinicalTrials.gov study NCT02495844. IPD Sharing: Not stated. Countries: 6. Publications: 0.
Study to Test the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy
ClinicalTrials.gov study NCT03370120. IPD Sharing: YES. Countries: 27. Publications: 0.
Predictors of Drug Resistant Epilepsy Among Pediatric Patients
ClinicalTrials.gov study NCT07241754. IPD Sharing: UNDECIDED. Countries: 0. Publications: 6.
Cortical Resections in Drug Resistant Epilepsy
ClinicalTrials.gov study NCT04553354. IPD Sharing: Not stated. Countries: 0. Publications: 13.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.